Showing results (171-180 of 189) with videos related to
Sort By:
Pageof 19
Annals of the New York Academy of Sciences|February 17, 2000
Regulation of postimplantation mouse embryonic growth by maternal vasoactive intestinal peptideC Y Spong, S J Lee, S K McCune, et al.The Journal of Pharmacology and Experimental Therapeutics|August 1, 1993
A decomposition product of a contaminant implicated in L-tryptophan eosinophilia myalgia syndrome affects spinal cord neuronal cell death and survival through stereospecific, maturation and partly interleukin-1-dependent mechanismsD E Brenneman, S W Page, M Schultzberg, et al.Investigative Ophthalmology & Visual Science|January 7, 1998
Vasoactive intestinal peptide stimulation of human trabecular meshwork cell growthS W Koh, T H Yeh, S M Morris, et al.Genes, Brain, and Behavior|January 22, 2005
Different levels of gamma-synuclein mRNA in the cerebral cortex of dominant, neutral and submissive rats selected in the competition testA Pinhasov, S E Ilyin, J Crooke, et al.Breast Cancer Research and Treatment|October 27, 2001
VIP receptor antagonists and chemotherapeutic drugs inhibit the growth of breast cancer cellsT W Moody, J Leyton, D Chan, et al.Nature|October 13, 1988
Neuronal cell killing by the envelope protein of HIV and its prevention by vasoactive intestinal peptideD E Brenneman, G L Westbrook, S P Fitzgerald, et al.Journal of Neurochemistry|August 1, 1983
Monoclonal antibodies against vasoactive intestinal polypeptide: studies of structure and related antigensI Gozes, R J Milner, F T Liu, et al.Endocrinology|February 2, 1999
Maternal regulation of embryonic growth: the role of vasoactive intestinal peptideC Y Spong, S J Lee, S K McCune, et al.Life Sciences|January 1, 1997
PACAP hybrid: a new PACAP receptor antagonistJ R Pisegna, J Leyton, T Coelho, et al.Cancer Research|August 1, 1996
Breast cancer growth is inhibited by vasoactive intestinal peptide (VIP) hybrid, a synthetic VIP receptor antagonistH Zia, T Hida, S Jakowlew, et al.Pageof 19